Glucotrol Xl (Glipizide)

Glucotrol XL is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan.

• Improves fasting and post‑prandial blood glucose levels when used with diet and exercise.
• Can be combined with other oral antidiabetic agents such as metformin or thiazolidinediones.
• May be prescribed for patients who require once‑daily dosing to enhance adherence.
• Used in adults when sulfonylurea therapy is appropriate and renal function is adequate.
• May be used as part of combination therapy with basal insulin when oral agents alone are insufficient.
• Can be considered when patients have difficulty adhering to multiple daily dosing schedules.

The safety profile of Glucotrol XL includes both frequent, less severe reactions and rare, potentially serious events.

Common

• Low blood sugar (hypoglycemia) symptoms such as sweating, shakiness, dizziness, or hunger.
• Nausea, abdominal discomfort, or upset stomach.
• Headache, sometimes accompanied by fatigue.
• Mild weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness, seizures, or need for emergency assistance.
• Allergic reactions including rash, itching, swelling of the face, lips, or tongue, and rare anaphylaxis.
• Blood disorders such as leukopenia, neutropenia, or thrombocytopenia.
• Significant elevations in liver enzymes indicating possible hepatic injury.

Before starting Glucotrol XL, certain health considerations should be reviewed to minimize risks.

• Assess renal and hepatic function, as impairment may require dose adjustment.
• Monitor blood glucose regularly to detect hypoglycemia early.
• Use caution in elderly patients who are more susceptible to low blood sugar.
• Avoid use during pregnancy or breastfeeding unless clearly indicated.
• Review any history of cardiovascular disease, as sulfonylureas may affect heart rhythm.
• Consider potential interactions with alcohol, which can enhance hypoglycemic effects.

Glucotrol XL can interact with several medicines, influencing its effectiveness or safety.

Avoid

• Concomitant use with other sulfonylureas or insulin, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which may increase glipizide levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask hypoglycemia symptoms.

Use with caution

• Beta‑blockers, which can blunt hypoglycemia warning signs.
• Thiazide diuretics, which may affect blood glucose control.
• Antidepressants like SSRIs that have been reported to alter glucose metabolism.